Advertisement
Canada markets close in 5 hours 53 minutes

  • S&P/TSX

    21,862.05
    +153.61 (+0.71%)
     

  • S&P 500

    5,010.82
    -0.30 (-0.01%)
     

  • DOW

    37,978.59
    +203.21 (+0.54%)
     

  • CAD/USD

    0.7280
    +0.0017 (+0.23%)
     

  • CRUDE OIL

    82.79
    +0.06 (+0.07%)
     

  • Bitcoin CAD

    89,292.73
    +3,161.21 (+3.67%)
     

  • CMC Crypto 200

    1,383.21
    +70.59 (+5.69%)
     

  • GOLD FUTURES

    2,396.40
    -1.60 (-0.07%)
     

  • RUSSELL 2000

    1,950.59
    +7.64 (+0.39%)
     

  • 10-Yr Bond

    4.6130
    -0.0340 (-0.73%)
     

  • NASDAQ

    15,528.22
    -73.28 (-0.47%)
     

  • VOLATILITY

    18.39
    +0.39 (+2.17%)
     

  • FTSE

    7,853.71
    -23.34 (-0.30%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6820
    -0.0001 (-0.01%)
     
MARKETS LIVE BLOG:

STOCKS OPEN MIXED AFTER ISRAEL STRIKE-FUELLED TUMBLE

Shares of Netflix, the first of the megacap techs to report, slide in early trading

Why Legalizing Hemp in US Opens Doors for Innovation

Adam Jones
Updated
Why Legalizing Hemp in US Opens Doors for Innovation

Canopy Growth is expected to spend nearly 5.3 million Canadian dollars in research and development in 2019, as seen in the above chart. Canopy Growth stated that it is developing CBD-based drugs to lower anxiety in dogs. The company believes that this development could then lead it to develop an anxiety-reducing drug for geriatric patients. For Canopy Growth, it is more important to find end uses of CBD products from hemp than to pursue the farming and extraction business.

Continue reading